Close

pCDCAR1 BCMA h(BBζ) (CAR-LC002)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-BCMA chimeric antigen receptor (CAR) is constructed for the engineering of T cell to target human BCMA. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-BCMA antibody linked to CD137 (4-1BB) and CD3ζ signaling domains. And the vector product was designed for the treatment of multiple myeloma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • BCMA
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Multiple myeloma
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • J6M0
  • Host
  • Human
  • Target Species
  • Human
  • Gene Name
  • TNF receptor superfamily member 17
  • Synonyms
  • BCMA;TNFRSF17; TNF receptor superfamily member 17; BCM; BCMA; CD269; TNFRSF13A;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data FCM

Fig.1 Dual staining byJ6M0-PerCP-Cy5.5 and CD38-PE Cy7 was done in MM1S and CD1381 patient MM cells. Immunostaining with J6M0 mAb (solid line) or isotype cont

CAR Construction : Latest CAR Construction

Fig.1 Dual staining byJ6M0-PerCP-Cy5.5 and CD38-PE Cy7 was done in MM1S and CD1381 patient MM cells. Immunostaining with J6M0 mAb (solid line) or isotype cont

Immunostaining with J6M0 mAb (solid line) or isotype control human IgG (iso IgG1,dashed line) was performed in CD1381 cells from additional MM patients.

Tai, Y. T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., ... & Anderson, K. C. (2014). Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood, The Journal of the American Society of Hematology, 123(20), 3128-3138.

CAR scFv data FCM

Fig.2 J6M0-mcMMAF selectively inhibits MM cell viability and colony formation via caspase 3/7-dependent apotosis.

CAR Construction : Latest CAR Construction

Fig.2 J6M0-mcMMAF selectively inhibits MM cell viability and colony formation via caspase 3/7-dependent apotosis.

All measurements were performed in triplicate.

Tai, Y. T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., ... & Anderson, K. C. (2014). Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood, The Journal of the American Society of Hematology, 123(20), 3128-3138.

CAR scFv data FCM

Fig.3 BCMA expression of patient samples by flow cytometry with J6M0-wtFc PE showing MFIr for individual patients.

CAR Construction : Latest CAR Construction

Fig.3 BCMA expression of patient samples by flow cytometry with J6M0-wtFc PE showing MFIr for individual patients.

BCMA expression by flow cytometry.

Lee, L., Bounds, D., Paterson, J., Herledan, G., Sully, K., Seestaller‐Wehr, L. M., ... & Yong, K. L. (2016). Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. British journal of haematology, 174(6), 911-922.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-BCMA (J6M0)h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-LC002). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.